1. ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
- Author
-
Happold, Caroline, Felsberg, Jörg, Clarke, Jennifer, Soffietti, Riccardo, Marosi, Christine, Krex, Dietmar, Ducray, François, Hau, Peter, Reijneveld, Jaap, Weyerbrock, Astrid, Wick, Antje, Reardon, David, Glas, Martin, Razis, Evangelia, Herrlinger, Ulrich, Tonn, Joerg-Christian, Carpentier, Antoine F, Lefranc, Florence, Rhun, Emilie Le, Verschuere, Tina, Golfinopoulos, Vassilis, Klein, Martin, Reifenberger, Guido, and Weller, Michael
- Subjects
Neurosciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Abstract BACKGROUND Survival in glioblastoma patients is usually in the range of 12–15 months, and less than 5% of patients survive 5 years from diagnosis. Little is known about factors influencing long-term survival. METHODS A consortium generously funded by the Brain Tumor Funders’ Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers patients with glioblastoma who survived for at least 5 years. The aim of the study is a better understanding of factors contributing to prolonged survival by assessment of (i) clinical features, (ii) molecular parameters, (iii) therapy and quality of life-related factors, and (iv) immunological parameters. The histopathological diagnosis of glioblastoma is centrally reviewed at study entry. Clinical characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Comprehensive molecular analyses are performed at the German Cancer Research Center (DKFZ), Germany. Immunological parameters are analyzed in Zurich, Switzerland. Alive patients are followed by neurocognitive assessments additionally. RESULTS At the cut-off of May 30, 2017, 182 patients have been registered by 17 sites; 107 patients are alive, more than half of which contribute to the neurocognitive assessments and patient-related outcome studies, as well as the immunological studies. First comprehensive results of disease characteristics with a cut-off of September 30, 2017, will be presented. CONCLUSIONS The collaborative effort of this consortium by comprehensive characterization of molecular parameters, immunological aspects, and individual clinical and therapy-related determinants will contribute to a better understanding of factors that modulate the course of this disease.
- Published
- 2017